In:
HNO, Springer Science and Business Media LLC, Vol. 69, No. 3 ( 2021-03), p. 172-184
Abstract:
Genomic aberrations (mutations, gene fusions, amplifications) and dysregulation of the fibroblast growth factor (FGF) receptor (FGFR) signaling pathway are frequently found in squamous cell carcinomas of the head and neck (HNSCCs). Targeted therapy with tyrosine kinase inhibitors (TKIs) or monoclonal antibodies directed against FGF receptors therefore represents a promising approach for the treatment of HNSCC. Objective This review article describes the current status of FGFR-directed therapies for head and neck tumors (especially HNSCC) and, in this context, discusses genomic alterations of the FGFR pathway as potential companion predictive biomarkers. Methods This article is based on searches of PubMed, ClinicalTrials.gov, and conference proceedings. Results First results prove the efficacy of TKIs both in HNSCC and in adenocarcinomas of the head and neck, especially in thyroid and adenocystic salivary gland carcinomas. Conclusion Early clinical and preclinical data point to the promise of biomarker-directed treatment of patients with head and neck tumors using FGFR-targeted TKIs.
Type of Medium:
Online Resource
ISSN:
0017-6192
,
1433-0458
DOI:
10.1007/s00106-020-00893-2
Language:
German
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
1459183-2
Permalink
